High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome
暂无分享,去创建一个
J. Cen | C. Chen | Wenying Yan | Shaoyan Hu | Y. Niu | Hai-long He | Li-hua Xu | Yang Guo | Qing Yan | H. He | Hai-long He
[1] M. Moore,et al. AHNS Series – Do you know your guidelines?: Assessment and management of malnutrition in patients with head and neck cancer: Review of the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines) , 2018, Head & neck.
[2] Jiajia Chen,et al. MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model , 2015, Oncotarget.
[3] Xuan Zhou,et al. MicroRNA-196b promotes cell proliferation and suppress cell differentiation in vitro. , 2015, Biochemical and biophysical research communications.
[4] F. Locatelli,et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations , 2014, Leukemia.
[5] J. Esteve,et al. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia , 2014, Leukemia.
[6] Bairong Shen,et al. Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer , 2014, Journal of Translational Medicine.
[7] P. Kearns,et al. Novel therapies for children with acute myeloid leukaemia , 2013, Leukemia.
[8] G. Inghirami,et al. Core binding factor acute myeloid leukaemia and c-KIT mutations. , 2013, Oncology reports.
[9] Jing Zheng,et al. Knocking down SMC1A inhibits growth and leads to G2/M arrest in human glioma cells. , 2013, International journal of clinical and experimental pathology.
[10] D. Johnston,et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. , 2012, Blood.
[11] R. Pieters,et al. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia , 2012, Pediatric blood & cancer.
[12] S. Lowe,et al. The microcosmos of cancer , 2012, Nature.
[13] C. Pui,et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Thiel,et al. The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. , 2011, Leukemia research.
[15] S. Koschmieder,et al. Low SMC1A protein expression predicts poor survival in acute myeloid leukemia. , 2010, Oncology reports.
[16] I. Bernstein,et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. , 2010, Blood.
[17] Jianjun Chen,et al. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. , 2010, Blood cells, molecules & diseases.
[18] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[19] J. Rowley,et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. , 2009, Blood.
[20] Lin Li,et al. [Research update on pharmacogenomics in acute leukemia - review]. , 2008, Zhongguo shi yan xue ye xue za zhi.
[21] Liya Gu,et al. Evidence That a Mutation in the MLH1 3′-Untranslated Region Confers a Mutator Phenotype and Mismatch Repair Deficiency in Patients with Relapsed Leukemia* , 2008, Journal of Biological Chemistry.
[22] D. Liang,et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples , 2008, Leukemia.
[23] T. Golub,et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia , 2007, Proceedings of the National Academy of Sciences.
[24] K. Basso,et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: Identification of candidate amplified and overexpressed genes , 2007, Genes, chromosomes & cancer.
[25] George P Cobb,et al. microRNAs as oncogenes and tumor suppressors. , 2007, Developmental biology.
[26] H. Dombret,et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.
[27] Y. Hayashi,et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. , 2006, Blood.
[28] [Suggestion of diagnosis and treatment of acute myelocytic leukemia in childhood]. , 2006, Zhonghua er ke za zhi = Chinese journal of pediatrics.
[29] U. Creutzig,et al. Pediatric acute myeloid leukemia: international progress and future directions , 2005, Leukemia.
[30] R. Arceci,et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891 , 2005, Leukemia.
[31] M. Felice,et al. Treatment strategy and long-term results in pediatric patients treated in two consecutive AML-GATLA trials , 2005, Leukemia.
[32] Chang-Zheng Chen,et al. MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.
[33] S. Meshinchi,et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia , 2005, Leukemia.
[34] R. Verhaak,et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.
[35] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[36] T. Tuschl,et al. Identification of Novel Genes Coding for Small Expressed RNAs , 2001, Science.